Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
OMass Therapeutics, a University of Oxford spin-out developing small-molecule drugs.
Why it matters: The round shows how European biotech investors are concentrating capital on platform-based drug discovery, with OMass's native mass spectrometry approach now funded through Phase 2.
British clinical-stage biopharma company Microbiotica announced the first close of a €42 million Series C round led by British Business Bank.
Why it matters: Microbiotica's Series C first close shows how genomics and machine learning are moving microbiome drug candidates into Phase 2 trials.
London-based Unravel Health raised €2.96 million led by Conduit EIS Impact Fund and Wrightwood.
Why it matters: The round shows how a saliva-based hormone reader is being funded toward early-access devices in 2027, with the same sensing technology already tested on other markers.
Stride, the preventive health membership founded by Olympic medalist Andrew Steele.
Why it matters: Stride's seed round shows how consumer preventive health is being built around lab diagnostics and an AI copilot, with retention as the open question.
Scarlet, founded by ex-Babylon Health medical AI engineers, raised a $50M Series B led by Headline.
Why it matters: Scarlet's $50M round shows how AI medical device certification is becoming its own business, with named customers and a regulatory bottleneck spelled out.
Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing
